Intellia Therapeutics/NTLA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Ticker

NTLA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Leonard

Employees

526

Headquarters

Cambridge, United States

NTLA Metrics

BasicAdvanced
$2.1B
Market cap
-
P/E ratio
-$5.37
EPS
1.83
Beta
-
Dividend rate
$2.1B
1.83221
$47.48
$19.37
1.3M
9.029
-36.27%
-43.60%
-39.21%
39.211
1.988
1.991
-1.63%
0.31%
-14.48%

What the Analysts think about NTLA

Analyst Ratings

Majority rating from 28 analysts.
Buy

NTLA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-371.62% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$29M
-20.17%
Net income
-$107M
-77.68%
Profit margin
-371.62%
-72.04%

NTLA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.81%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.40
-$1.38
-$1.46
-$1.12
-
Expected
-$1.32
-$1.50
-$1.45
-$1.38
-$1.23
Surprise
5.99%
-7.93%
0.75%
-18.81%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Intellia Therapeutics stock?

Intellia Therapeutics (NTLA) has a market cap of $2.1B as of June 15, 2024.

What is the P/E ratio for Intellia Therapeutics stock?

The price to earnings (P/E) ratio for Intellia Therapeutics (NTLA) stock is 0 as of June 15, 2024.

Does Intellia Therapeutics stock pay dividends?

No, Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Intellia Therapeutics dividend payment date?

Intellia Therapeutics (NTLA) stock does not pay dividends to its shareholders.

What is the beta indicator for Intellia Therapeutics?

Intellia Therapeutics (NTLA) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Intellia Therapeutics stock price target?

The target price for Intellia Therapeutics (NTLA) stock is $69.61, which is NaN% below the current price of $. This is an average based on projections from 23 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Intellia Therapeutics stock

Buy or sell Intellia Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing